Go Top

衛生福利部桃園醫院Taoyuan General Hospital, Ministry and Welfare

  • Total Beds1,052
  • Total Doctors213
  • AddressNo.1492, Zhongshan Rd., Taoyuan Dist.Taoyuan,Taoyuan City 330
  • ContactClinical Research Center, Taoyuan General Hospital, Ministry and Welfare

1. A Focal (Flagship) Hospital dedicated in clinical research development.

2. In the COVID-19 pandemic, TYGH served as the gateway hospital for tourists and citizens entering Taiwan and conducted multiple clinical research related to COVID-19. Such research include, but not limited to: New drug development, NRICM0101 clinical trial, Quinine IIT, COVID-19 rapid antigen test…etc.

3. Collaborating with National Health Research Institute Taiwan Cooperative Oncology Group to conduct cancer clinical research

Site Introduction

In order to encourage the development of biotechnology industry in Taiwan and to become the second Medical Center in Taoyuan City, Taoyuan General Hospital established the Clinical Research Center (CRC) in August, in 2018. We are new but continuously growing in providing high quality of service ; to secure compliance with Good Clinical Practice, ethics, regulatory contractual requirements by developing research policies and standards, as well as providing training and knowledge exchange opportunities to clinical investigators and other clinical research personnel.

Clinicl Trial Expertise

Infectious disease、Oncology、Chest、Nephrology、Cardiovascular disease、Chinese medicine

International Accreditation

GCP Inspection/audit



1. Since its establishment in 2018, the Clinical Research Center has collaborated with 39 domestic or international pharmaceutical companies, biotech consulting firms, contract research organizations, and national research institutes, and had conducted 62 clinical trials of medical devices and investigational medications (ranging from phase 1 to phase 4) combined.
2. Located in the center of Taoyuan City, It is with convenient transportation. In addition to being the gateway hospital for Taoyuan International airport, TYGH is also the designated hospital for TB prevention and treatment, AIDS treatment and care, COVID-19, high-risk pregnancy, and Emergency Response and Server Emergency Responsibility Hospital to serve and protect the health of the people.
3. Being the "Medical and Health Technology Innovation R&D Cooperating Hospital" of the National Health Research Institutes, TYGH is dedicated to promoting academic research cooperation and talent cultivation; Moreover, the Cancer Center of the hospital cooperates with the "Taiwan Cooperative Oncology Group" (TCOG) to conduct cancer-related clinical trials to strengthen medical research and the development of novel medical technology.
4. Since the outbreak of COVID-19, TYGH had had collaborated with the National Health Research Institutes to participate in the project of collecting specimens of SARS-CoV-2 pneumonia and had cared for the most COVID-19 patients in the country. TYGH collected more than 30% of the total specimens nationwide. Meanwhile, adhering to the central policy, in collaboration with 11 ministerial hospitals, the clinical trial of chloroquine in the treatment of novel coronavirus infection initiated by the investigators was carried out and was not only published in international journals but also the Central Epidemic Command Center's formal report.
5. TYGH collaborated with several domestic and foreign pharmaceutical companies and trusted research institutions, domestic and abroad, to conduct clinical trials of COVID-19 drugs ranging from Phase II to Phase IV. These investigational medications included vaccines development, medications in various forms and doses to treat COVID-19, including oral medications, nasal sprays, intravenous injections, and subcutaneous injections… etc., in an attempt to discover effective drugs for the prevention and treatment of COVID-19 as soon as possible.
6. In addition, in collaboration with the National Institute of Traditional Chinese Medicine, TYGH conducted clinical research on Chinese medicine of Qing-guan No. 1 and No. 2 (NRICM0101 and NRICM0102 respectively). The distinguished result was published in a peer-reviewed international academic journal (Pharmacological Research). To combat the spread of COVID-19, TYGH also collaborated with Industrial Technology Research Institute and multiple biotech companies to conduct clinical trials validating COVID-19 antigen or antibody detection technology to increase the speed and accuracy of rapid detection of COVID-19 virus providing effective and convenient tools for early diagnosis of COVID-19 in time of the pandemic.




1. Tseng YH, Lin SJS, Hou SM, Wang CH, Cheng SP, Tseng KY, Lee MY, Lee SM, Huang YC, Lin CJ, Lin CK, Tsai TL, Lin CS, Cheng MH, Fong TS, Tsai CI, Lu, YW, Lin JC, Huang YW, Hsu WC, Kuo HH, Wang LH, Liaw CC, Wei WC, Tsai KC, Shen YC, Chiou WF, Lin JG, Su YC. Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis. Pharmacological Research, 2022 Oct; 184:106412.


2. Estrada JA, Cheng CY, Ku SY, Hu HC,77 Yeh HW, Lin YC, Chen CP, Cheng SH, Janssen R, Lin IF. An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901. Vaccines (Basel). 2022 Apr 21;10(5):655.


3. Sheng WH, Chang SY, Lin PH, Hsieh MJ, Chang HH, Cheng CY, Yang HC, Pan CF, Ieong SM, Chao TL, Chen JP, Cheng SH, Chang SC. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination. J Formos Med Assoc. 2022 Mar 16;121(4):766-777.


4. Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, Maggiolo F, Degen O, Taylor S, Blair E, Man C, Wynne B, Oyee J, Underwood M, Curtis L, Bontempo G, van Wyk J. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With HIV-1: Week 48 Results From the Phase 3, Non-inferiority SALSA Randomized Trial. Clin Infect Dis. 2022 Mar 2;ciac130.


5. A. Jayk Bernal, M.M. Gomes da Silva, D.B. Musungaie, E. Kovalchuk, A. Gonzalez, V. Delos Reyes, A. Martín-Quirós, Y. Caraco, A. Williams-Diaz, M.L. Brown, J. Du, A. Pedley, C. Assaid, J. Strizki, J.A. Grobler, H.H. Shamsuddin, R. Tipping, H. Wan, A. Paschke, J.R. Butterton, M.G. Johnson, Cheng CY and C. De Anda, for the MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022 Feb 10;386(6):509-520.


6. Huang CF, Kuo HT, Chang TS, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Yu ML. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. Sci Rep. 2021 Dec 6;11(1):23473. doi: 10.1038/s41598-021-03006-3.


7. Huang CF, Tseng KC, Cheng PN, Hung CH, Lo CC, Peng CY, Bair MJ, Yeh ML, Chen CH, Lee PL, Lin CY, Kuo HT, Chen CT, Yang CC, Huang JF, Tai CM, Hu JT, Lin CL, Su WW, Tsai WL, Huang YH, Cheng CY, Yu ML. Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: a large cohort study from the nationwide HCV Registry Program (TACR). Clin Gastroenterol Hepatol. 2021;S1542-3565(21)00819-3.


8. Chen CP, Lin YC, Chen TC, Tseng TY, Wong HL, Kuo CY, Lin WP, Huang SR, Wang WY, Liao JH, Liao CS, Hung YP, Lin TH, Chang TY, Hsiao CF, Huang YW, Chung WS, Cheng CY, Cheng SH; Taiwan HCQ Study Group. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS One. 2020 Dec 2;15(12):e0242763.